Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
AJR Am J Roentgenol ; 205(4): W451-60, 2015 Oct.
Article in English | MEDLINE | ID: mdl-26397352

ABSTRACT

OBJECTIVE: Nonresectoscopic endometrial ablation techniques are being used as an alternative first-line management for menorrhagia. With these techniques, patients are at risk of developing delayed complications including painful obstructed menses, such as central hematometra and cornual hematometra, and postablation tubal sterilization syndrome. Pregnancy and the detection of endometrial cancer after ablation pose challenges in management. CONCLUSION: Radiologists should recognize the normal imaging findings in patients who have undergone endometrial ablation, be aware of the causes of treatment failure, and accurately identify delayed complications associated with these procedures.


Subject(s)
Endometrial Ablation Techniques/adverse effects , Uterine Diseases/diagnosis , Uterine Diseases/surgery , Female , Humans , Uterine Diseases/etiology
2.
J Am Acad Dermatol ; 56(4): 584-7, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17184879

ABSTRACT

Four patients with stable or progressive cutaneous T-cell lymphoma treated with oral bexarotene received oral rosiglitazone. After 16 weeks of combination therapy, skin score decreased in two patients. Pruritus was alleviated in 3 of 4 patients, whereas quality of life was unchanged. Adverse events included hyperlipidemia, anemia, neutropenia, and lymphopenia.


Subject(s)
Lymphoma, T-Cell, Cutaneous/drug therapy , Lymphoma, T-Cell, Cutaneous/pathology , Tetrahydronaphthalenes/administration & dosage , Thiazolidinediones/administration & dosage , Aged , Anticarcinogenic Agents/administration & dosage , Bexarotene , Biopsy, Needle , Dose-Response Relationship, Drug , Drug Administration Schedule , Drug Therapy, Combination , Female , Follow-Up Studies , Humans , Immunohistochemistry , Lymphoma, T-Cell, Cutaneous/mortality , Male , Maximum Tolerated Dose , Middle Aged , Neoplasm Staging , Pilot Projects , Risk Assessment , Rosiglitazone , Single-Blind Method , Survival Analysis , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...